Enzalutamide + NSAA + LHRHA or Surgical Castration
Phase 3Active 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Prostatic Neoplasms
Conditions
Prostatic Neoplasms
Trial Timeline
Mar 1, 2014 โ Jun 30, 2027
NCT ID
NCT02446405About Enzalutamide + NSAA + LHRHA or Surgical Castration
Enzalutamide + NSAA + LHRHA or Surgical Castration is a phase 3 stage product being developed by Astellas Pharma for Prostatic Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT02446405. Target conditions include Prostatic Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02446405 | Phase 3 | Active |
Competing Products
20 competing products in Prostatic Neoplasms